Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment (Q33403298)

26 July 2017

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment (English)

1 reference

26 July 2017

1 reference

Neal J Weinreb

1

1 reference

26 July 2017

Jack Goldblatt

2

1 reference

26 July 2017

Jacobo Villalobos

3

1 reference

26 July 2017

Joel Charrow

4

1 reference

26 July 2017

J Alexander Cole

5

1 reference

26 July 2017

Marcelo Kerstenetzky

6

1 reference

26 July 2017

Stephan vom Dahl

7

1 reference

26 July 2017

Carla Hollak

8

1 reference

26 July 2017

14 September 2012

1 reference

Journal of Inherited Metabolic Disease

26 July 2017

1 reference

26 July 2017

36

1 reference

26 July 2017

543-553

1 reference

26 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-012-9528-4

26 July 2017

0 references

cites work

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Vascular complications after splenectomy for hematologic disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

The long-term international safety experience of imiglucerase therapy for Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Individualization of long-term enzyme replacement therapy for Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Enzyme therapy for Gaucher disease: the first 5 years.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3648688

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9528-4

Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9528-4

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9528-4

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9528-4

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22976765

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22976765

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22976765

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10545-012-9528-4

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference